AdvaMed Urges A Different Approach To User Fee Performance Goals
This article was originally published in The Gray Sheet
Executive Summary
AdvaMed says it wants FDA to set new user fee performance goals that better reflect the total time it takes to get a product through FDA and onto the market.
You may also be interested in...
In User Fee Talks, FDA Investigates Pre-market Review Delays
As FDA user fee negotiations move ahead, the agency is conducting a root cause analysis to determine why the time it takes to complete pre-market device reviews is increasing.
In User Fee Talks, FDA Investigates Pre-market Review Delays
As FDA user fee negotiations move ahead, the agency is conducting a root cause analysis to determine why the time it takes to complete pre-market device reviews is increasing.
New-Tech "Grace Period" Among Industry Recommendations For ACOs
AdvaMed says it wants CMS to permit at least a five-year grace period from accountable care organization payment rules for physician early adopters of new medical technologies and treatments.